FDA warned Hanlim Pharm over serious sterile manufacturing violations, including poor aseptic practices and airflow problems, at its South Korea plant.
What happened
FDA inspected Hanlim Pharm’s drug manufacturing facility in Gyeonggi-do, South Korea, from April 16 to April 24, 2026. FDA found poor aseptic practices, inadequate airflow visualization studies, inadequate cleaning and sterilization, weak environmental monitoring, and a deficient visual inspection program and quality unit. FDA said the company’s response was inadequate and cited similar violations in a previous warning letter.
What FDA found
FDA observed operators reaching over open sterile tubes and bottles, using items directly over open containers, and working in the highest-cleanliness area with a visibly stained gown.
21 CFR 211.113(b)FDA said airflow visualization studies showed airflow did not protect open aseptic processing areas and could draw lower-quality cleanroom air into the highest-cleanliness zone.
21 CFR 211.113(b)FDA found critical container and closure contact surfaces were not sterilized but wiped with spore-killing disinfectants.
21 CFR 211.42(c); 21 CFR 211.110(a)FDA found environmental monitoring locations and frequencies were not adequately justified and did not sufficiently sample near containers, closures, and barriers facing the highest-cleanliness area.
21 CFR 211.42(c); 21 CFR 211.110(a)FDA found the visual inspection program lacked routine defect categorization and acceptance criteria despite significant defect rates.
21 CFR 211.42(c); 21 CFR 211.110(a)FDA found the quality unit did not ensure a stability program supporting expiration dating or contemporaneous records for environmental and personnel monitoring.
21 CFR 211.22; 21 CFR 211.166(a); 21 CFR 211.194(a)
What FDA wants
FDA tells Hanlim to respond in writing within 15 business days with comprehensive corrective action plans, independent assessments, and a qualified consultant, and to notify FDA before resuming manufacturing. FDA may withhold approvals or refuse US admission until the violations are corrected.
Who should pay attention
- brands and distributors that buy sterile drugs from Hanlim Pharm
- US agents and importers of Hanlim products
- quality teams at sterile drug manufacturers
This is a summary. Read the original letter on fda.gov.